Maze Therapeutics Advances Potential Gene Therapy Involving ATXN2

Maze Therapeutics Advances Potential Gene Therapy Involving ATXN2

291428

Maze Therapeutics Advances Potential Gene Therapy Involving ATXN2

Maze Therapeutics is advancing the development of a lead gene therapy candidate for amyotrophic lateral sclerosis (ALS), which works by suppressing the activity of a potent genetic modifier called ATXN2. Genetic modifiers are genes or genetic variants that can increase or reduce the severity of a condition without necessarily causing the disease themselves. Such modifiers are thought to contribute to the variability in clinical symptoms and disease progression observed in ALS patients. The company’s other lead candidates include…

You must be logged in to read/download the full post.